Kim Soo-Kyung, Pak Daewoo, Lee Jong-Han, Ryu Sook Won
Department of Laboratory Medicine, Ewha Womans University College of Medicine, Seoul 07985, Republic of Korea.
Division of Data Science, College of Software Digital Healthcare Convergence, Yonsei University, Wonju 26493, Republic of Korea.
Diagnostics (Basel). 2025 May 29;15(11):1374. doi: 10.3390/diagnostics15111374.
This study investigated hematological and biochemical parameters, including cell population data (CPD), to evaluate their association with severity in COVID-19 and non-COVID-19 patients. Identifying these parameters could aid in disease monitoring and clinical decision-making. : A retrospective analysis of 8401 patients, including 603 COVID-19 cases and 7546 non-COVID-19 cases, were conducted. Complete blood count (CBC) and routine chemistry results obtained near the time of real-time polymerase chain reaction testing were analyzed to assess their associations with disease severity. A matched cohort analysis was performed to adjust for potential confounding factors, such as age and sex. : COVID-19 patients with elevated neutrophil side fluorescence light (NE-SFL), platelet-to-lymphocyte ratio (PLR), glucose, and aspartate aminotransferase (AST), along with decreased plateletcrit, were more likely to experience severe outcomes, such as hospitalization or death. In addition, decreased hemoglobin, lymphocyte side scatter (LY-SSC), and albumin, as well as increased leukocyte and monocyte side scatter (MO-SSC), were associated with a greater severity, regardless of COVID-19 status. : We identified hematologic and chemical assay biomarkers that correlate with severe COVID-19. These findings may provide important information regarding the disease progression and clinical management. Incorporating these biomarkers into clinical decision support systems could facilitate personalized treatment strategies, optimize resource allocation, and enable real-time severity stratification.
本研究调查了血液学和生化参数，包括细胞群体数据（CPD），以评估它们与新冠肺炎患者和非新冠肺炎患者病情严重程度的关联。确定这些参数有助于疾病监测和临床决策。：对8401例患者进行了回顾性分析，其中包括603例新冠肺炎病例和7546例非新冠肺炎病例。分析了在实时聚合酶链反应检测时获得的全血细胞计数（CBC）和常规化学检测结果，以评估它们与疾病严重程度的关联。进行了匹配队列分析，以调整年龄和性别等潜在混杂因素。：中性粒细胞侧向荧光强度（NE-SFL）、血小板与淋巴细胞比值（PLR）、血糖和天冬氨酸转氨酶（AST）升高，同时血小板压积降低的新冠肺炎患者更有可能出现住院或死亡等严重后果。此外，无论是否感染新冠肺炎，血红蛋白降低、淋巴细胞侧向散射光（LY-SSC）和白蛋白降低，以及白细胞和单核细胞侧向散射光（MO-SSC）增加都与病情更严重有关。：我们确定了与重症新冠肺炎相关的血液学和化学检测生物标志物。这些发现可能为疾病进展和临床管理提供重要信息。将这些生物标志物纳入临床决策支持系统可以促进个性化治疗策略，优化资源分配，并实现实时严重程度分层。
